Brain metastases
AS Achrol, RC Rennert, C Anders, R Soffietti… - Nature Reviews …, 2019 - nature.com
An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
YL Wu, R Dziadziuszko, JS Ahn, F Barlesi… - … England Journal of …, 2024 - Mass Medical Soc
Background Platinum-based chemotherapy is the recommended adjuvant treatment for
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …
Treatment for brain metastases: ASCO-SNO-ASTRO guideline
MA Vogelbaum, PD Brown, H Messersmith… - 2022 - academic.oup.com
Purpose To provide guidance to clinicians regarding therapy for patients with brain
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …
Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research brain metastases working …
Purpose Broadening trial eligibility to improve accrual and access and to better reflect
intended-to-treat populations has been recognized as a priority. Historically, patients with …
intended-to-treat populations has been recognized as a priority. Historically, patients with …
[HTML][HTML] Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX …
ABSTRACT Background The phase III ALEX study in patients with treatment-naive
advanced anaplastic lymphoma kinase mutation-positive (ALK+) non-small-cell lung cancer …
advanced anaplastic lymphoma kinase mutation-positive (ALK+) non-small-cell lung cancer …
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Structural gene rearrangements resulting in gene fusions are frequent events in solid
tumours. The identification of certain activating fusions can aid in the diagnosis and effective …
tumours. The identification of certain activating fusions can aid in the diagnosis and effective …
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
Purpose The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1%
to 2% of non–small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with …
to 2% of non–small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with …
The evolving landscape of brain metastasis
Metastasis, involving the spread of systemic cancer to the brain, results in neurologic
disability and death. Current treatments are largely palliative in nature; improved therapeutic …
disability and death. Current treatments are largely palliative in nature; improved therapeutic …
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Purpose: We report the intracranial efficacy of selpercatinib, a highly potent and selective
RET inhibitor, approved in the United States for RET fusion-positive non–small cell lung …
RET inhibitor, approved in the United States for RET fusion-positive non–small cell lung …